Kingdon Capital Management L.L.C. Has $19.55 Million Stake in Edwards Lifesciences Corporation $EW

Kingdon Capital Management L.L.C. grew its stake in Edwards Lifesciences Corporation (NYSE:EW) by 175.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 251,400 shares of the medical research company’s stock after acquiring an additional 160,100 shares during the period. Edwards Lifesciences accounts for about 2.4% of Kingdon Capital Management L.L.C.’s investment portfolio, making the stock its 6th biggest position. Kingdon Capital Management L.L.C.’s holdings in Edwards Lifesciences were worth $19,551,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Norges Bank bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after acquiring an additional 4,805,819 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Marshall Wace LLP increased its position in Edwards Lifesciences by 127.5% during the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after acquiring an additional 3,864,908 shares during the period. Finally, Viking Global Investors LP acquired a new stake in Edwards Lifesciences in the 3rd quarter worth about $238,688,000. 79.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on EW. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Evercore reiterated an “outperform” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 5th. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Finally, BTIG Research reissued a “buy” rating and set a $103.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,897,284.92. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total value of $1,103,960.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 61,718 shares of company stock valued at $5,236,281. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Down 3.3%

EW opened at $81.82 on Monday. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The company’s 50-day moving average is $82.41 and its 200 day moving average is $81.58. The firm has a market capitalization of $47.52 billion, a P/E ratio of 44.71, a PEG ratio of 2.13 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.